



**BENCH TO
BEDSIDE**
URO-ONCOLOGY
GU CANCER TRIAD



Register now!

SCIENTIFIC PROGRAMME COMMITTEE



Peter
BLACK
Canada



Peter
HAMMERER
Germany



Pilar
LAGUNA
Turkey



Rafael
SANCHEZ-SALAS
France

December 13–14, 2019 in Berlin, Germany

www.siu-urology.org



#B2BGUCancerTriad

Day 1

Friday, December 13, 2019

*All times listed are Central European Standard Time (GMT+1)



TIME	SESSION TITLE	INVITED SPEAKERS
0800	Welcome and Introduction	Peter Black, Canada and Pilar Laguna, Turkey
Clinical Development of Immunotherapy for Bladder Cancer		
0815–0835	Immunotherapy in Metastatic Urothelial Carcinoma	Petros Grivas, United States
Where to next?		
0835–0850	Perioperative Immunotherapy for MIBC	Andrea Necchi, Italy
0850–0905	Combining Trimodal Therapy with Checkpoint Blockade	Wassim Kassouf, Canada
0905–0920	Immunotherapy and Evolving Therapies in NMIBC	Peter Black
0920–0945	Discussion / Q&A	Moderator: Peter Black Petros Grivas Wassim Kassouf Andrea Necchi
<i>0945–1010 Health Break</i>		
Clinical Development of Immunotherapy for Kidney Cancer		
1010–1030	Immunotherapy in Metastatic RCC	Christian Kollmannsberger, Canada
1030–1115	Multimodal Therapy of mRCC: Case-based Panel (to include discussion of cytoreductive Nx and SABR or surgery of mets)	Moderator: Michael Staehler, Germany Axel Bex, The Netherlands Dirk Böhmer, Germany Christian Kollmannsberger
1115–1135	Role of Perioperative IO and Targeted Therapy in High-risk RCC	Viktor Grünwald, Germany
Adverse Events/Toxicities		
1135–1220	Case-based Discussions on Adverse Events / Toxicities Associated with Immunotherapy	Moderator: Kilian Gust, Austria Christian Kollmannsberger Pablo Maroto Rey, Spain Andrea Necchi Srikala Sridhar, Canada
<i>1220–1335 Lunch Break</i>		
Biomarkers of Response to Therapy		
1335–1420	Developing Biomarkers for Clinical Utilization in Advanced Bladder Cancer: Panel Discussion	Moderator: Andrea Necchi Petros Grivas Gopa Iyer, United States Tilman Todenhöfer, Germany
1420–1450	The Microbiome in Tumor Immunology	Lisa Derosa, France
<i>1450–1510 Health Break</i>		
The Pipeline		
1510–1530	FGFR Inhibitors in Urothelial Carcinoma	Gopa Iyer
1530–1550	Antibody Drug Conjugates in Urothelial Carcinoma	Srikala Sridhar
1550–1630	Discussion	Moderators: Peter Black and Pilar Laguna Gopa Iyer Srikala Sridhar
1630	Concluding Remarks	Peter Black and Pilar Laguna

This programme has been accredited by the Ärztekammer Niedersachsen for 12 training points.

This programme has been accredited by the Ärztekammer Berlin for 12 training points.

The B2B Uro-oncology: GU Cancer Triad Meeting, Berlin, Germany, 13/12/2019-14/12/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Day 2

Saturday, December 14, 2019

*All times listed are Central European Standard Time (GMT+1)



TIME	SESSION TITLE	INVITED SPEAKERS
Part I. Prostate Cancer I		
0800–0810	Welcome Message	Peter Hammerer, Germany and Rafael Sanchez-Salas, France
0810–0830	Who and When: Germ-line DNA Testing in Prostate Cancer Patients	Thorsten Schlomm, Germany
Management of High Risk Non-metastatic Prostate Cancer		
0830–0845	What is important for the surgeon?	Rafael Sanchez-Salas
0845–0905	What is important for the radiotherapist?	Alberto Bossi, France
0905–0925	Discussion (with Q&A)	Moderator: Peter Hammerer Alberto Bossi Rafael Sanchez-Salas Thorsten Schlomm
Managing Oligometastatic Prostate Cancer		
0925–0945	Treatment of the Primary	Prasanna Sooriakumaran, United Kingdom
0945–1005	Definitive Treatment of the Mets	Dirk Böhmer, Germany
1005–1025	Systemic Therapy	Srikala Sridhar, Canada
1025–1110	Case-based Panel Discussion (with Q&A)	Moderator: Rafael Sanchez-Salas Dirk Böhmer Karim Fizazi, France Peter Hammerer Prasanna Sooriakumaran
1110–1130 Health Break		
Part II. Prostate Cancer II		
1130–1155	Managing Biochemical Recurrence after Definitive Local Therapy: Case-based Panel Discussion (with Q&A)	Moderator: Peter Hammerer Alberto Bossi Axel Heidenreich, Germany Pablo Maroto Rey, Spain Derya Tilki, Germany Rafael Sanchez-Salas
1155–1215	Sequencing of Systemic Therapy for mCSPC & mCRPC	Karim Fizazi
1215–1235	Liquid Biopsy to Support Clinical Decision-making	Klaus Pantel, Germany
1235–1255	nmCRPC: Treatment Options in an Endangered Disease State	Antonio Alcaraz, Spain
1255–1345 Lunch Break		
mCRPC Systemic Therapy Pipeline		
1345–1405	Immunotherapy	Pablo Maroto Rey
1405–1425	PARP Inhibitors	Peter Hammerer
1425–1445	PSMA-Theranostics	Frederik Giesel, Germany
1445	Concluding Remarks	Peter Hammerer and Rafael Sanchez-Salas

This programme has been accredited by the Ärztekammer Niedersachsen for 12 training points.

This programme has been accredited by the Ärztekammer Berlin for 12 training points.

The B2B Uro-oncology: GU Cancer Triad Meeting, Berlin, Germany, 13/12/2019-14/12/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



**BENCH TO
BEDSIDE**
URO-ONCOLOGY
GU CANCER TRIAD



Meeting Venue
Berlin Marriott Hotel
Inge-Beisheim-Platz 1
10785 Berlin, Germany

Registration Rates

Urologists
Medical Oncologists
Radiation Oncologists
Other Specialists

€150

Residents
Trainees
Fellows
Nurses

€65

To register:
<https://bit.ly/2NO2UrO>